SWOT Analysis
Strength: HCG plays a vital role in early pregnancy by supporting placental function. It is available across various dosage forms like injections, drops and powder.
Weakness: Frequent administration of HCG is required which leads to poor patient compliance. There are also concerns regarding its long term effects when used for weight loss.
Opportunity: Rising infertility rates and obesity prevalence offer significant opportunities. Product line extensions with added nutrients can further aid the weight management application.
Threats: Competition from alternative fertility treatments and counterfeit HCG products circulating in the market pose major threats. Stringent regulations for its weight loss usage in some countries restricts market growth.
Key Takeaways
The Global Human Chorionic Gonadotropin (HCG) Market Growth is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing awareness about fertility treatments and rise in obesity.
The North America region is projected to dominate the HCG market during the forecast period due to availability of advanced healthcare facilities and rising infertility rates in the region.
Regional analysis:
Asia Pacific is expected to exhibit the highest growth rate over the forecast period owing to growing medical tourism, increasing healthcare expenditure and rising disposable incomes in developing countries like India and China.
Key players operating in the Human Chorionic Gonadotropin (HCG) market are Merck & Co., Inc., Ferring B.V.,Fresenius SE & Co.KGaA,Lupin,Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited, Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd.
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek